Novartis’ canakinumab fails to improve overall survival in lung cancer trial
Two additional Phase III trials will continue to investigate canakinumab
Read More
Tag: canakinumab
Novartis’ Ilaris first drug approved for Still’s disease
Ilaris works by blocking the effects of IL-1 and suppressing inflammation in patients with this autoinflammatory disorder
Read More
Novartis pulls EU filing for canakinumab
Novartis has pulled back its application to market canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI in Europe.
Read More
Novartis drug cuts cardiovascular risk in heart attack survivors
An experimental antibody being developed by Novartis has cut cardiovascular risk in patients who have survived a heart attack in a late-stage study.
Read More
Novartis bags three new approvals for Ilaris
Novartis has picked up three new indications for its anti-inflammatory Ilaris in the US, allowing its use to treat three rare and distinct types of Periodic Fever Syndromes.
Read More
